3940 TRUST WAY, HAYWARD, CA
Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Benitec Biopharma Engages Ernst & Young as New Independent Auditor
Change in Independent Registered Public Accounting Firm - Ernst & Young Appoi...
Releases Full Year 2026 Financial Results and Provides Operational Update
Director Appointment - David Friedman Joins Benitec Biopharma Board
Releases Third Quarter 2026 Financial Results and Provides Operational Update
Releases Second Quarter 2026 Financial Results and Provides Operational Update
2025 Annual Meeting Results; Directors Elected and Auditor Ratified
FY 2025
Q1
Amended Annual Report
Q4
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload